World Library  
Flag as Inappropriate
Email this Article

Lonza Group

Article Id: WHEBN0012305782
Reproduction Date:

Title: Lonza Group  
Author: World Heritage Encyclopedia
Language: English
Subject: Alusuisse, Nucleofection, Granta Park, Bertilimumab, Trastuzumab emtansine
Collection: Biotechnology Companies, Chemical Companies of Switzerland
Publisher: World Heritage Encyclopedia

Lonza Group

Lonza Group AG
Type Aktiengesellschaft
Traded as SIX: LONN, SGX: O6Z
Industry Chemicals
Founded 1897
Headquarters Basel, Switzerland
Key people Richard Ridinger (CEO), Rolf Soiron (Chairman)
Products fine chemicals, chemical synthesis equipment, custom manufacturing of chemicals and related products
Revenue CHF 2.680 billion (2010)[1]
Operating income CHF 374 million (2010)[1]
Profit CHF 291 million (2010)[1]
Total assets CHF 4.778 billion (end 2010)[1]
Total equity CHF 2.387 billion (end 2010)[1]
Employees 11,400 (2012)

Lonza Group is a fine and performance chemicals, custom manufacturing of biopharmaceuticals, chemical synthesis capabilities, detection systems and services for the bioscience sector.[4][5]


Lonza was founded in 1897 in the small Swiss town of Gampel, situated in the canton of Valais, taking its name from the nearby river. Initially the company produced electricity used to manufacture chemicals such as calcium carbide. Lonza moved to neighbouring Visp (where it retains a production site today) in 1909 and began manufacturing synthetic fertilisers, and moves into vitamins, acids, intermediates and additives followed. In 1974, the group merged with aluminium firm Alusuisse, after which the group moved into the biotechnology sector. Lonza de-merged from the Alusuisse-Lonza Group in 1999 and listed on the SWX Swiss Exchange. The company has expanded in the United States and acquired smaller biopharmaceutical units in recent years. In October 2011, Lonza acquired American firm Arch Chemicals for $1.4 billion, as a result becoming the world's largest manufacturer of biocides.[6]


  1. ^ a b c d e "Annual Results 2010" (PDF). Lonza Group. Retrieved 5 February 2011. 
  2. ^ Lonza to invest USD 150 million in Genome Valley, Hyderabad Bio Asia 2010 announced
  3. ^ Lonza to invest Rs 250 cr in Genome Valley | Business Standard
  4. ^ Allotment 30 Acres of Land in the “Genome Valley”
  5. ^ Lonza Group to set up a bio pharma unit at Genome Valley
  6. ^ Simonian, Haig (11 July 2011). "Lonza in $1.4bn acquisition of Arch Chemicals".  

External links

  • Official website

This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from Hawaii eBook Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.